SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Pfizer - Quaterly Results

17 May 2024 Evaluate
Revenue showed a marginal decline at Rs. 5466.30 millions. For the quarter ended March 2024, as compared to corresponding quarter of last year.The company has announced a 37.96% increase in its profits to Rs . 1788.60  millions for the  quarter ended March 2024 compared to Rs. 1296.50 millions in the corresponding quarter in the previous year.Operating profit for the quarter ended March 2024 rose to 2645.60 millions as compared to 2132.50 millions of corresponding quarter ended March 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 5466.30 5726.40 -4.54 21931.70 24247.60 -9.55 21931.70 24247.60 -9.55
Other Income 751.30 313.80 139.42 1805.10 1010.50 78.63 1805.10 1010.50 78.63
PBIDT 2645.60 2132.50 24.06 8158.10 9099.10 -10.34 8158.10 9099.10 -10.34
Interest 69.50 25.30 174.70 154.10 133.90 15.09 154.10 133.90 15.09
PBDT 2576.10 1911.30 34.78 8083.50 9295.20 -13.04 8083.50 9295.20 -13.04
Depreciation 137.50 264.10 -47.94 622.80 1055.10 -40.97 622.80 1055.10 -40.97
PBT 2438.60 1647.20 48.05 7460.70 8240.10 -9.46 7460.70 8240.10 -9.46
TAX 650.00 350.70 85.34 1947.40 2000.80 -2.67 1947.40 2000.80 -2.67
Deferred Tax 163.10 -315.30 -151.73 361.10 -519.10 -169.56 361.10 -519.10 -169.56
PAT 1788.60 1296.50 37.96 5513.30 6239.30 -11.64 5513.30 6239.30 -11.64
Equity 457.50 457.50 0.00 457.50 457.50 0.00 457.50 457.50 0.00
PBIDTM(%) 48.40 37.24 29.96 37.20 37.53 -0.87 37.20 37.53 -0.87

Pfizer Share Price

4446.20 26.35 (0.60%)
05-Jun-2026 09:31 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1791.90
Dr. Reddys Lab 1272.10
Cipla 1391.65
Zydus Lifesciences 1089.00
Lupin 2284.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×